IC
VNDA icon

Inscription Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Inscription Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Hold
63,878
– – 0.03% 465
2026
Q1 		$441K Hold
63,878
– – 0.05% 391
2025
Q4 		$563K Buy
63,878
+47,646
+294% +$262K 0.06% 328
2025
Q3 		$81K Buy
+16,232
New +$75.1K 0.01% 619

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inscription Capital's VNDA Position: Q2 2026 in Review

Inscription Capital held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 63,878 shares worth $391K. The position accounts for 0.03% of the portfolio, ranked #465.

Inscription Capital first reported a position in VNDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $563K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Inscription Capital held 63,878 shares of Vanda Pharmaceuticals worth $391K as of Q2 2026.
  • Inscription Capital left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
  • Vanda Pharmaceuticals made up 0.03% of Inscription Capital's portfolio in Q2 2026, its #465 holding.
  • Inscription Capital first reported a position in Vanda Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Inscription Capital's Vanda Pharmaceuticals position peaked at $563K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.